These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Epstein-Barr virus-associated lymphoproliferative disorder developed after anti-thymocyte globulin therapy in a patient with bone marrow failure associated with T-cell large granular lymphocytic leukemia. Sumi M; Watanabe M; Sato K; Shimizu I; Ueki T; Akahane D; Ueno M; Ichikawa N; Asano N; Kobayashi H Rinsho Ketsueki; 2011 Nov; 52(11):1782-7. PubMed ID: 22185802 [TBL] [Abstract][Full Text] [Related]
8. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. Peres E; Savasan S; Klein J; Abidi M; Dansey R; Abella E J Clin Microbiol; 2005 Jul; 43(7):3540-3. PubMed ID: 16000501 [TBL] [Abstract][Full Text] [Related]
9. [Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis subsequent to rabbit antithymocyte globulin administration and successfully treated with rituximab in a patient with aplastic anemia]. Nagata H; Fujino T; Muramatsu A; Kawaji Y; Kuriyama K; Oshiro M; Hirakawa Y; Iwai T; Uchiyama H Rinsho Ketsueki; 2018; 59(4):407-413. PubMed ID: 29743400 [TBL] [Abstract][Full Text] [Related]
10. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222 [TBL] [Abstract][Full Text] [Related]
12. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. Muramatsu H; Takahashi Y; Shimoyama Y; Doisaki S; Nishio N; Ito Y; Hama A; Shimada A; Yagasaki H; Ito M; Kojima S Int J Hematol; 2011 Jun; 93(6):779-781. PubMed ID: 21559814 [TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702 [TBL] [Abstract][Full Text] [Related]
14. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Hoshino Y; Kimura H; Tanaka N; Tsuge I; Kudo K; Horibe K; Kato K; Matsuyama T; Kikuta A; Kojima S; Morishima T Br J Haematol; 2001 Oct; 115(1):105-11. PubMed ID: 11722419 [TBL] [Abstract][Full Text] [Related]
15. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972 [TBL] [Abstract][Full Text] [Related]
19. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia. Ohata K; Iwaki N; Kotani T; Kondo Y; Yamazaki H; Nakao S Acta Haematol; 2012; 127(2):96-9. PubMed ID: 22178718 [TBL] [Abstract][Full Text] [Related]